Assistant Professor in Ligand and (Pro)Drug Development
The Faculty of Science and Leiden Academic Center for Drug Research are looking for an Assistant Professor in Ligand and (Pro)Drug Development
- Einsteinweg, Leiden, Zuid-Holland
- Tijdelijk contract / Tijdelijke opdracht
- Development of antibiotic or anticancer (pro)drugs and evaluation of their efficacy in vitro or in preclinical studies;
- Development of ligands and antigens (e.g. carbohydrates, peptides and lipids) to enhance specificity of nanomedicines for cell targeting;
- Acquisition of external funds;
- Training of a new generation of young academics;
- Active contribution to innovative teaching and to the translation of research into new classes, practical courses, and seminars;
- Convey the gained knowledge, insights, and success stories to society.
Nowadays, bacterial infections and cancer form a large focus point for the development of drugs based on both biologics and small molecules. Within the investment programme of the faculty of Science, we aim to focus on the discovery and development of drugs and ligands to improve the efficiency of nanomedicines. Nanomedicines provide a tool to treat a variety of life-threatening illnesses and infectious diseases. However, these systems often require the development of prodrugs for side specific release or targeting moieties for cell specific uptake. Therefore, we aim to strengthen our team in the biotherapeutics division with a chemist providing such knowledge and willing to contribute to the development of nanomedicines.
With this initiative we aim to expand our research on prodrugs and targeting structures for immunomodulatory, anticancer and antibiotic drugs, with a focus on the treatment of bacterial infections. In collaboration, LACDR and IBL aim to greatly increase our potential to design novel delivery systems that enable and optimize the clinical applications of nanomedicines.
To that end, we aim to establish a faculty that focuses on the design, the application of innovative delivery systems, and mechanism of action studies to enable the development of cell- and disease-specific drugs.
- A doctorate in chemistry, biochemistry, biomedicine or another relevant discipline;
- A strong background in one or multiple of the following disciplines: (bio)organic chemistry, chemical biology, glycobiology, infectious diseases, and antibiotics or anticancer agents
- Wide experience of and demonstrable success in external fundraising and helping others to raise funds;
- A solid scientific track record, as is evident, for example, from publications in renowned international journals and active participation in international academic and professional networks;
- A strong focus on (interdisciplinary) collaboration and encouraging team achievements;
- Strong teaching abilities, enthusiasm and drive.
We offer a full-time fixed-term position up to six years (depending on qualifications), with a possibility of a tenured position depending on funding and performance. Salary ranges from € 3746 to € 5.825 gross per month (pay scale 11-12) in accordance with the Collective Labour Agreement for Dutch Universities).
Leiden University offers an attractive benefits package with additional holiday (8%) and end-of-year bonuses (8.3 %), training and career development and sabbatical leave. Our individual choices model gives you some freedom to assemble your own set of terms and conditions. Candidates from outside the Netherlands may be eligible for a substantial tax break. For more information, see the website.
Leiden University requires teaching staff to obtain the University Teaching Qualification (UTQ). If the successful applicant does not already possess this qualification or its equivalent, he/ she must be willing to obtain this qualification within two years. There’s a language proficiency of minimum level Cl required for staff who will teach in English.
Leiden University is strongly committed to diversity within its community and especially welcomes applications from members of underrepresented groups.
Enquiries can be made to Matthias Barz, Division of BioTherapeutics, email email@example.com.